Get the Stockscreener App
1.08
3.57%
-0.04
After Hours:
1.04
-0.04
-3.70%
Dermata Therapeutics Inc Stock (DRMA) Latest News
Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria
Crown Labs completes acquisition of Revance Therapeutics - Investing.com
Dermata Unveils Game-Changing Skin Disease Treatment Progress: CEO Reveals What's Next - StockTitan
Acne Vulgaris Market Expected to rise, 2034 | Pelthos - openPR
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment - ACCESS Newswire
Dermata Therapeutics Signs Clinical Trial Collaboration Agreement with Revance Therapeutics for Topical Treatment StudyDermata Therapeutics, Inc. (NASDAQ: DRMA) revealed in an 8-K filing that on January 17, 2025, the company entered into a Clinical T - Defense World
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire
Dermata Therapeutics Announces Private Placement of $2.4 Million in Securities SAN DIEGO, CA – Dermata Therapeutics, Inc. (NASDAQ: DRMA) disclosed in a filing on January 21, 2025, that it has entered into a securities purchase agreement for a private - Defense World
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire
Biotech Alert: Searches spiking for these stocks today - TipRanks
Dermata Therapeutics secures $2.55 million in private placement - MSN
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Dermata Therapeutics, Inc. announced that it has received $2.550008 million in funding -January 22, 2025 - Marketscreener.com
Dermata Therapeutics Secures $2.55M Private Placement with Strong Insider Participation - StockTitan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Dermata Therapeutics announces $2.55M private offering - MSN
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Yahoo Finance
Dermata, Revance test new hyperhidrosis treatment By Investing.com - Investing.com Australia
Dermata, Revance test new hyperhidrosis treatment - MSN
Dermata and Revance Partner on First Needle-Free Botulinum Treatment for Excessive Sweating - StockTitan
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Accenture Plc (ACN-N) QuotePress Release - The Globe and Mail
Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register
Dermata Therapeutics (NASDAQ:DRMA) Trading Up 1.2% – Still a Buy? - Defense World
Dermata Therapeutics, Inc. Receives Approval from FDA for the Proprietary Name Xyngarifor for Its Phase 3 Clinical Drug Candidate in Acne - Marketscreener.com
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) - AccessWire
Dermata's Acne Treatment 'Xyngari' Secures FDA Name Approval; Phase 3 Data Expected March 2025 - StockTitan
Dermata Therapeutics stock hits 52-week low at $1.05 By Investing.com - Investing.com UK
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - AccessWire
Dermata Secures Key Patent for Revolutionary Acne Treatment DMT310 Ahead of Phase 3 Results - StockTitan
The Best Warren Buffett Stocks to Buy With $500 Right Now - The Globe and Mail
DRMAWDermata Therapeutics, Inc. Warrant Latest Stock News & Market Updates - StockTitan
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - AccessWire
Dermata Therapeutics, Inc. Completes Enrollment in First Pivotal DMT310 Phase 3 Star-1 Clinical Trial for Acne - Marketscreener.com
Dermata Completes Phase 3 Trial Enrollment for Novel Weekly Acne Treatment - StockTitan
ARMISTICE CAPITAL, LLC Increases Stake in Dermata Therapeutics I - GuruFocus.com
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dermata Therapeutics stock hits 52-week low at $1.2 amid steep decline - Investing.com UK
Earnings Flash (DRMA) DERMATA THERAPEUTICS Reports Q3 Loss $-2.04 - Marketscreener.com
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - AccessWire
Dermata Hits 50% Enrollment in Phase 3 Acne Trial, Raises $7.8M in 2024 | DRMAW Stock News - StockTitan
Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024 - The Manila Times
Dermata stock hits 52-week low at $1.22 amid market challenges - Investing.com Australia
Sponge Power: Dermata's Revolutionary Acne Treatment Trial Results Due In 2025 - RTTNews
Analyzing DRMA’s price-to-book ratio for the last quarter - US Post News
Dermata stock hits 52-week low at $1.28 amid market challenges - Investing.com UK
Acne Vulgaris Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2024-2034), States DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health - Barchart
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):